Pages
Products
GFP Adeno-Associated Virus ( AAV-LS1 )

GFP Adeno-Associated Virus ( AAV-LS1 )

Cat.No. :  AAV00461Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 2 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00461Z
Description This virus is a reporter AAV with capsid engineering / modification. GFP AAV-LS1 particles contain engineered capsid derived from AAV serotype 2 (AAV2) which has insertion of peptides NDVRSAN* at I588. The target cell type of this capsid engineered AAV is tumor cells (CML), CD34+cells.
Reporter GFP
Serotype AAV Serotype 2
Target Gene GFP
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Adeno-associated virus (AAV) provides an extremely versatile basis for the bioengineering of recombinant gene transfer vectors, as its low genetic complexity facilitates the cloning, packaging, and delivery of therapeutic gene expression cassettes. Fueling the promise of AAV is the large number of natural viral isolates that possess unique properties that can be modulated or enhanced, including tissue specificity, transgene expression efficiency, and evasion of pre-existing or induced anti-AAV antibodies. This repurposing is often achieved in a high-throughput manner, involving the generation and iterative, top-down selection of synthetic AAV capsid libraries that are diversified using techniques such as DNA family shuffling, ancestral reconstruction, or peptide display. Alternatively, specific vector properties can also be established in a rational bottom-up approach by introducing targeted changes in the capsid. AAV-LS1 particles are derived from AAV serotype 2 (AAV2). The key modification in AAV-LS1 is the insertion of the peptide sequence NDVRSAN* at position I588 of the capsid protein. This peptide is carefully designed to alter the tropism of the virus, thereby improving the ability of the virus to recognize and infect specific cell types more efficiently than unmodified AAV2. The engineered peptides of the modified capsid recognize specific receptors or surface markers expressed on chronic myeloid leukemia (CML) cells and CD34+ hematopoietic stem cells, allowing for precise and efficient delivery of genetic payloads. This makes AAV-LS1 particularly suitable for targeted cancer therapy and stem cell research.
Customer Q&As
Is AAV gene therapy safe?

A: Adeno-associated virus (AAV) gene therapy has been studied extensively and is generally considered safe, but like any medical treatment, it does carry some risks.

Why is GFP used in transfection?

A: When the gene of interest is inserted into target cells along with GFP, those cells will start producing green fluorescent protein and glow under UV light if the transfection is successful. This allows researchers to easily visualize and track cells that have taken up the introduced DNA, making GFP a powerful tool for genetic and cell biology research.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Highly Efficient Tumor Targeting

The GFP AAV-LS1 has proven remarkably efficient in targeting and transducing CML cells in our lab experiments. The engineered capsid modification ensures high specificity, making it an invaluable tool for our cancer research.

Canada

06/22/2021

Excellent results

The specificity and efficiency of the GFP AAV-LS1 have significantly enhanced the accuracy and reliability of my experiments. The high GFP expression in CD34+ populations has allowed for precise monitoring and downstream analysis.

Canada

02/19/2024

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction